Mary Beth Scholand - Concepedia

Author

Mary Beth Scholand

Also Known As

Bridget Collins, Danielle M. Rius, Fischer, Hans, Heidi Erickson, Hilda Pomroy, Jerry A. Krishnan, Kapil Patel, Laura A. Pace, M. B. Scholand, M. Scholand

161

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

University of Utah University of Colorado Denver University of Michigan National Jewish Health Johns Hopkins University

About

Mary Beth Scholand is an author at University of Utah specializing in medicine, pulmonary disease, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	3.3K
2	Public Health	4	4	673
3	Epidemiology	4	4	443
4	Emergency Medicine	2	2	65
5	Social Sciences	1	1	134

Mary Beth Scholand

Publications

Citations

H-Index

Page 1

	Year	Citations
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial Donald P. Tashkin, Michael D. Roth, Philip J. Clements, The Lancet Respiratory Medicine Sls IiMycophenolate MofetilInflammatory Lung DiseaseAdvanced Lung DiseaseSystemic Scleroderma	2016	1K
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, The Lancet Respiratory Medicine Inbuild TrialParallel-group TrialAdvanced Lung DiseasePulmonary FibrosisPulmonary Medicine	2020	522
Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort Annette T. Hastie, Fernando J. Martínez, Jeffrey L. Curtis, The Lancet Respiratory Medicine EpidemiologyBlood Eosinophil ConcentrationsAdvanced Lung DiseaseMedicineClinical Epidemiology	2017	307
Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort MeiLan K. Han, P. Miguel Quibrera, Elizabeth E. Carretta, The Lancet Respiratory Medicine	2017	304
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel, The Lancet Respiratory Medicine FibrosisAntifibrotic TherapyInflammatory Lung DiseaseAdvanced Lung DiseaseLung Inflammation	2019	275
A Candidate Gene Approach Identifies the CHRNA5-A3-B4 Region as a Risk Factor for Age-Dependent Nicotine Addiction Robert B. Weiss, Timothy B. Baker, Dale S. Cannon, PLoS Genetics Substance UseGeneticsGenetic EpidemiologyEpigeneticsCandidate Gene Approach	2008	270
Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development Adam M Gustafson, Raffaella Soldi, Christina Anderlind, Science Translational Medicine	2010	265
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study Joshua J. Solomon, Sonye K. Danoff, Felix Woodhead, The Lancet Respiratory Medicine Rheumatoid DisorderRheumatologyPharmacologyClinical TrialsPulmonary Pharmacology	2022	182
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis Ganesh Raghu, Mary Beth Scholand, João A. de Andrade, European Respiratory Journal	2016	168
Relationship of <i>BMPR2</i> Mutations to Vasoreactivity in Pulmonary Arterial Hypertension C. Gregory Elliott, Eric W. Glissmeyer, Gregory T. Havlena, Circulation	2006	146

Page 1